Therapeutic Market Outlooks

Insomnia
Publication Date: January 2008

Tables and Figures

Tables
Table 1: National Institutes of Health (NIH) Insomnia
Classifications ...................................................................... 4
Table 2: Insomnia Patient Population Model ............................ 8
Table 3: U.S. Insomnia Market Model, 2004-2013 .................. 12
Table 4: U.S. Insomnia Market Model, 2004-2013 .................. 13
Table 5: Marketed Products in the United States.................... 20
Table 6: Benzodiazpines Used in the Treatment of Insomnia ... 21
Table 7: Insomnia Clinical Trial Efficacy Endpoints ................. 24
Table 8: Forecasts of Future Market Trends .......................... 25
Table 9: Ambien/Ambien CR – Revenue Models ..................... 26
Table 10: Ambien – Commercial Strength ............................. 26
Table 11: Ambien CR – Commercial Strength ........................ 26
Table 12: Zolpidem/Zolpidem CR – Revenue Models .............. 28
Table 13: Sonata/zaleplon – Revenue Models ........................ 30
Table 14: Sonata – Commercial Strength .............................. 30
Table 15: Lunesta/eszopiclone – Revenue Models .................. 32
Table 16: Lunesta – Commercial Strength............................. 32
Table 17: Rozerem – Revenue Model.................................... 34
Table 18: Rozerem – Commercial Strength............................ 34
Table 19: Restoril/temazepam – Revenue Model.................... 36
Table 20: Restoril/temazepam – Commercial Strength............ 36
Table 21: Indiplon – Revenue Model .................................... 38
Table 22: Silenor – Revenue Model ...................................... 40
Table 23: Eplivanserin/volinanserin – Revenue Models............ 42
Table 24: ORG 50081 – Revenue Model................................ 44
Table 25: Almorexant – Revenue Model ................................ 46
Table 26: Drugs in Development.......................................... 50

Figures
Figure 1: Theoretical Patient Population Breakdown by
Severity and Duration of Insomnia ......................................... 5

www.avoslifesciences.com reports@avoslifesciences.com
Figure 2: Theoretical Patient Population Breakdown by
Sub-type of Insomnia ........................................................... 6
Figure 3: Theoretical Patient Population Breakdown – Patient
Interface with Healthcare System........................................... 6
Figure 4: AVOS Insomnia Population Projections by Year .......... 8
Figure 5: The Diagnostic Approach to Insomnia..................... 14
Figure 6: Insomnia Treatment Algorithm............................... 15
Figure 7: AVOS Physician Panel Product Ratings (Scale of
1-10) ................................................................................ 18
Figure 8: Timeline of Major Insomnia Market Events .............. 21
Figure 9: Ambien/Ambien CR – U.S. Market Share Forecasts ... 26
Figure 10: Ambien/Ambien CR – U.S. Revenue Forecasts........ 26
Figure 11: Zolpidem/Zolpidem CR – U.S. Market Share
Forecasts .......................................................................... 28
Figure 12: Zolpidem/Zolpidem CR – U.S. Revenue Forecasts ... 28
Figure 13: Sonata/zaleplon – U.S. Market Share Forecasts ...... 30
Figure 14: Sonata/zaleplon – U.S. Revenue Forecasts............. 30
Figure 15: Lunesta/eszopiclone – U.S. Market Share
Forecasts .......................................................................... 32
Figure 16: Lunesta/eszopiclone – U.S. Revenue Forecasts....... 32
Figure 17: Rozerem – U.S. Market Share Forecast.................. 34
Figure 18: Rozerem – U.S. Revenue Forecast ........................ 34
Figure 19: Restoril/temazepan – U.S. Market Share Forecasts . 36
Figure 20: Restoril/temazepan – U.S. Revenue Forecasts........ 36
Figure 21: Indiplon – U.S. Market Share Forecast .................. 38
Figure 22: Indiplon – U.S. Revenue Forecast ......................... 38
Figure 23: Silenor – U.S. Market Share Forecast .................... 40
Figure 24: Silenor – U.S. Revenue Forecast ........................... 40
Figure 25: Eplivanserin/volinanserin – U.S. Market Share
Forecasts .......................................................................... 42
Figure 26: Eplivanserin/volinanserin – U.S. Revenue
Forecasts .......................................................................... 42
Figure 27: ORG 50081 – U.S. Market Share Forecast.............. 44
Figure 28: ORG 50081 – U.S. Revenue Forecast .................... 44
Figure 29: Almorexant – U.S. Market Share Forecast .............. 46
Figure 30: Almorexant – U.S. Revenue Forecast .................... 46
Figure 31: Clinical Success Rates of Insomnia Agents:
1990-Present ..................................................................... 48

www.avoslifesciences.com reports@avoslifesciences.com